Abstract: Objective To investigate the safty of MIG in anti-inflammatory and hepatoprotective therapy of patients with decompensated liver cirrhosis (DLC). Methods There are 118 cases with decompensated cirrhosis treated with magnesium isoglycyrrhizinate (80 mg/day) (MIG) alone or combined with other one or two kinds of hepatoprotective drugs treatment above two weeks retrospectively. The blood ions and blood pressure were measured completely, and the male patients were 81 cases and famale patients were 37 cases, while the average age was (54.6 ± 12.7) (14-84) years old. Among total of 118 patients, there were 52 cases of virus-related cirrhosis (VRC), 35 cases of alcoholic cirrhosis (AC) and 31 cases of autoimmune-related cirrhosis (ARC). The difference of serum ions and systolic blood pressure (SBP), as well as diastolic blood pressure (DBP) at the first and second week were tested and analysed. Results To patients on DLC, there was a significant increase in the normal range about blood potassium (P = 0.015) and calcium (P = 0.016) respectively than that before the therapy, while no increase showed on the other parameters. All the patients on VRC and AC had no meaningful change in serum ions no matter they got on therapy after one week or two. Slight increase showed on blood potassium (P = 0.043) of patients with ARC in the normal range after a week’s therapy, while no difference reflected on other parameters significantly. DLC and VRC patients had meaningful reduction on SBP (P = 0.007, 0.027) after they went on MIG theray after one week, while no difference on DBP and no significant changes reflected on the other two groups. Conclusions Whether MIG alone or in combination with the other anti-inflammatory medications about two weeks, observers didn’t find water-sodium retention and blood pressure elevation on the patients with DLC, therefore, short-term treatment of MIG ensures safty.